NewcelX Ltd.(NCEL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NCEL NewcelX Ltd.

已收盘 10-08 16:00:00 EDT

3.11

+0.08

+2.47%

盘后3.11

+0.000.00%

16:10 EDT

最高3.11	最低2.89	成交量7,303
今开2.93	昨收3.04	日振幅7.25%
总市值1,796万	流通市值834.66万	总股本577.61万
成交额2.21万	换手率0.27%	流通股本268.38万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NCEL","market":"US","secType":"STK","nameCN":"NewcelX Ltd.","latestPrice":3.11,"timestamp":1791489600000,"preClose":3.035,"halted":0,"volume":7303,"hourTrading":{"tag":"盘后","latestPrice":3.11,"preClose":3.11,"latestTime":"16:10 EDT","volume":7,"amount":20.88,"timestamp":1791490204795,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.02471169686985164,"floatShares":2683800,"shares":5776100,"eps":-0.509695,"marketStatus":"已收盘","change":0.075,"latestTime":"10-08 16:00:00 EDT","open":2.925,"high":3.1101,"low":2.89,"amount":22087,"amplitude":0.072521,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.509695,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791532800000},"marketStatusCode":5,"adr":0,"listingDate":1611896400000,"exchange":"NASDAQ","adjPreClose":3.035,"postHourTrading":{"tag":"盘后","latestPrice":3.11,"preClose":3.11,"latestTime":"16:10 EDT","volume":7,"amount":20.88,"timestamp":1791490204795,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.745375},"requestUrl":"/m/hq/s/NCEL","defaultTab":"news","newsList":[{"id":"1188974254","title":"NewcelX任命世界知名糖尿病治疗先驱Camillo Ricordi博士加入科学顾问委员会","url":"https://stock-news.laohu8.com/highlight/detail?id=1188974254","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188974254?lang=zh_cn&edition=full","pubTime":"2026-07-08 21:22","pubTimestamp":1783516979,"startTime":"0","endTime":"0","summary":"NewcelX Ltd.宣布，已正式聘请国际知名糖尿病治疗领域先驱Camillo Ricordi博士加入其科学顾问委员会。这一重要人事任命标志着公司在糖尿病创新疗法研发方面迈出了关键一步。\nRicordi博士在胰岛移植和免疫耐受研究领域享有崇高声誉，其开创性工作为糖尿病治疗带来了革命性前景。他的加入预计将为NewcelX的科学战略方向提供权威指导，并加速相关治疗方案的临床转化进程。\n公司表示，此次引进顶尖学术人才，旨在强化研发管线的科学基础，并进一步提升在细胞治疗领域的核心竞争力。业界观察人士认为，该举措可能对NewcelX未来在代谢疾病治疗市场的布局产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121312334","title":"Newcelx宣布FDA临床前会议成功，为Ncel-101启动1型糖尿病临床试验铺平道路","url":"https://stock-news.laohu8.com/highlight/detail?id=1121312334","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121312334?lang=zh_cn&edition=full","pubTime":"2026-07-01 21:35","pubTimestamp":1782912913,"startTime":"0","endTime":"0","summary":"Newcelx宣布，其与FDA就Ncel-101项目举行的临床前会议取得圆满成功，为推进该疗法针对1型糖尿病的临床试验明确了清晰的路径。此次会议成果标志着公司在该创新疗法的开发进程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCEL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174997049","title":"Newcelx更新企业演示文稿，重点展示与Eledon制药战略合作后的1型糖尿病旗舰项目，瑞士生物技术会议前揭晓","url":"https://stock-news.laohu8.com/highlight/detail?id=1174997049","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174997049?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:37","pubTimestamp":1776685035,"startTime":"0","endTime":"0","summary":"Newcelx已更新其企业演示文稿，着重强调与Eledon制药达成战略合作后的1型糖尿病旗舰项目。这一更新恰逢瑞士生物技术会议召开前夕，凸显了公司对该项目的重视与推进决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.newcelx.com","stockEarnings":[{"period":"1week","weight":-0.013},{"period":"1month","weight":-0.094},{"period":"3month","weight":-0.2651},{"period":"6month","weight":0.2189},{"period":"1year","weight":-0.8342},{"period":"ytd","weight":0.5974}],"compareEarnings":[{"period":"1week","weight":0.0191},{"period":"1month","weight":0.0091},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.1439},{"period":"1year","weight":0.1616},{"period":"ytd","weight":0.1398}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"NewcelX Ltd.于2015年6月10日成立。 该公司是一家创新的生物制药公司，致力于发现和开发可改善罕见中枢神经系统疾病的改善生命的药物疗法。NewcelX专注于开发变革性的干细胞衍生疗法，用于治疗1型糖尿病。公司基于已验证的人类多能干细胞（hPSC）平台，其主导项目旨在通过可扩展的、现成的细胞替代疗法来恢复胰岛素的功能性分泌。NewcelX正在推进一种针对1型糖尿病的综合治疗方案，该方案整合了细胞疗法、免疫保护和转化科学，以满足尚未满足的关键医疗需求。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.029374},{"month":2,"riseRate":0.5,"avgChangeRate":0.017842},{"month":3,"riseRate":0.5,"avgChangeRate":-0.051042},{"month":4,"riseRate":0.166667,"avgChangeRate":0.033493},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.027493},{"month":6,"riseRate":0.666667,"avgChangeRate":0.117944},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.183199},{"month":8,"riseRate":0.5,"avgChangeRate":0.026303},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.066094},{"month":10,"riseRate":0,"avgChangeRate":-0.208179},{"month":11,"riseRate":0.2,"avgChangeRate":-0.070852},{"month":12,"riseRate":0.4,"avgChangeRate":-0.07921}],"exchange":"NASDAQ","name":"NewcelX Ltd.","nameEN":"NewcelX Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NewcelX Ltd.(NCEL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供NewcelX Ltd.(NCEL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"NewcelX Ltd.,NCEL,NewcelX Ltd.股票,NewcelX Ltd.股票老虎,NewcelX Ltd.股票老虎国际,NewcelX Ltd.行情,NewcelX Ltd.股票行情,NewcelX Ltd.股价,NewcelX Ltd.股市,NewcelX Ltd.股票价格,NewcelX Ltd.股票交易,NewcelX Ltd.股票购买,NewcelX Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NewcelX Ltd.(NCEL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供NewcelX Ltd.(NCEL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}